Corporate Banner
Satellite Banner
Scientific Community
Become a Member | Sign in
Home>News>This Article

Genzyme Celebrates Fifth Annual World MS Day

Published: Thursday, May 30, 2013
Last Updated: Thursday, May 30, 2013
Bookmark and Share
Company’s long-term commitment to MS extends beyond innovative therapies to new programs that address global needs of community.

Genzyme together with the global multiple sclerosis (MS) community of patients, advocates and healthcare providers, will today celebrate World MS Day, a campaign created by the Multiple Sclerosis International Federation (MSIF) to raise awareness of MS. Genzyme is committed to making a difference in the lives of people living with MS with differentiated therapies that include once-daily, oral AUBAGIO® and LEMTRADA™, as well as a research pipeline focused on innovative approaches to treating MS. LEMTRADA (alemtuzumab) is currently under regulatory review.

As a proud supporter of World MS Day and other MSIF programs, Genzyme has diversified its franchise offering with innovative grants and partnerships designed to broaden awareness about MS and address remaining unmet needs within the community. 2013 grants and partnerships include:

The International Progressive MS Collaborative: Genzyme is an active supporter for this global platform, developed to leverage the unique expertise and resources of its experts to expedite the development of effective disease modifying and symptom management therapies for progressive forms of MS.

MSIF Infrastructure Grant: Genzyme has provided a grant to the MSIF that will initiate, support and encourage the development of new MS organizations in Middle East and Pan-Asia regions, where there is currently little support, limited information and low awareness of the disease. MSIF has already begun to see the emergence of patient-led organizations and Genzyme’s support will help strengthen the MSIF’s ability to meet the needs of people with MS in these regions.

"I Ride with MS:" Genzyme is the sole sponsor of the "I Ride with MS" program from the National Multiple Sclerosis Society that celebrates cyclists participating in the Society’s annual Bike MS series who are also living with MS. By providing visibility to riders living with MS, “I Ride with MS” participants are not only strengthening cyclists' commitment to create a world free of MS, but also serve to inspire all who are part of the MS movement. Bike MS consists of 100 cycling events across the country that aim to raise money for MS research and other services supported by the Society.

MS One to One™: Because each patient’s experience with MS is unique, Genzyme has also created MS One to One to provide customized, one-to-one support with a dedicated, MS certified team of nurses available 24/7, who offer information and answers to frequently asked questions about MS, and more.

“Today and every day, millions of people living with MS and their families will face challenges with incredible strength and determination,” said Bill Sibold, SVP and Head of MS, Genzyme. “While MS can be a devastating diagnosis, there has never been a more hopeful time than now with new and exciting treatment advances. As a supporter of World MS Day, our MS team at Genzyme is inspired by those living with MS. We are proud to participate in this year’s campaign and are committed to engaging the global community across the spectrum of care. Our pledge to the community is that we will take on the challenge of MS together.”

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,800+ scientific posters on ePosters
  • More than 4,000+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Genzyme’s LEMTRADA™ Application for MS Accepted for Review by the FDA
Genzyme also reports very encouraging early launch indicators for AUBAGIO® (teriflunomide) in U.S.
Tuesday, January 29, 2013
Scientific News
Genetic Basis of Fatal Flu Side Effect Discovered
A group of people with fatal H1N1 flu died after their viral infections triggered a deadly hyperinflammatory disorder in susceptible individuals with gene mutations linked to the overactive immune response, according to a recent study.
Developing Drug Resistance may be a Matter of Diversity for Tuberculosis
Researchers have probed the bacteria that causes tuberculosis, Mycobacterium tuberculosis, to learn more about how individual bacterial cells change and adapt while in the human body.
Surprising Trait Found in Anti-HIV Antibodies
Scientists at The Scripps Research Institute (TSRI) have new weapons in the fight against HIV.
Some Gut Microbes May Be Keystones of Health
University of Oregon scientists have found that strength in numbers doesn’t hold true for microbes in the intestines. A minority population of the right type might hold the key to regulating good health.
Essential Component of Antiviral Defense Identified
Infectious disease researchers at the University of Georgia have identified a signaling protein critical for host defense against influenza infection.
Single Vaccine for Chikungunya, Related Viruses May be Possible
What if a single vaccine could protect people from infection by many different viruses? That concept is a step closer to reality.
Is Allergy the Price We Pay for Our Immunity to Parasites?
New findings help demonstrate the evolutionary basis for allergy.
Blocking the Transmission Of Malaria Parasites
Vaccine candidate administered for the first time in humans in a phase I clinical trial led by Oxford University’s Jenner Institute, with partners Imaxio and GSK.
Mucus – the First Line of Defence
Researchers reveal the important role of mucus in building a good defence against invaders.
Antibody Targets Key Cancer Marker
University of Wisconsin-Madison researchers have created a molecular structure that attaches to a molecule on highly aggressive brain cancer and causes tumors to light up in a scanning machine.

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos